---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044969"
form_type: "8-K/A"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:29:09.133549+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio corrects Series G warrant expiration to May 20, 2026; clinical trial for IBIO-600 cleared in Australia

## Summary
- Series G warrants expire at 5:00 p.m. ET on May 20, 2026 (30 trading days after public announcement).
- Outstanding Series G warrants to purchase ~11.07M shares; 36.14M shares of common stock outstanding as of April 17, 2026.
- Received CTN acknowledgement from Australia's TGA and ethics approval for Phase 1 trial of IBIO-600; first dosing expected Q2 2026.
- Pre-funded warrants for 13.79M shares issued upon exercise of Series G warrants.

## SEC filing metadata
- accession: 0001104659-26-044969
- form_type: 8-K/A
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/0001104659-26-044969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465926044969/ibio-20260408x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044969
- JSON: https://secwatch.observer/filing/0001104659-26-044969.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.